Current Trends in Control and Monitoring of Subvisible Particulate Matter in Biotherapeutics
Posted on February 21, 2018
Satish K. Singh
Head of Drug Product Process Development
Drug Product Services
Prof. Dr. Hanns-Christian Mahler
Head of Drug Product Services
Drug Product Services
Lonza Pharma and Biotech, Basel, Switzerland
Particulate matter in the context of sterile parenteral products is a broad term that covers all manner of particles and agglomerates that may be found in the product. Particulate matter in sterile parenteral products is an undesirable characteristic, except in the case of sterile suspensions. Howev...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
agglomerates, biotherapeutics, Control and Monitoring of Subvisible Particulate Matter, Lonza Pharma and Biotech, Particles, particulate matter, Prof. Dr. Hanns-Christian Mahler, Satish K. Singh, sterile parenteral products, sterile suspensions, Subvisible Particulate Matter
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
